@article{20.500.13003/19917,
year = {2023},
month = {8},
url = {https://hdl.handle.net/20.500.13003/19917},
abstract = {Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing practice in patients with mCRC in Spanish centers.
Multicenter, observational retrospective study that included patients newly diagnosed with mCRC or who progressed to a metastatic stage from early/localized stages.
Three hundred patients were included in the study from May 2020 through May 2021, with a median age of 68 years, and two hundred twenty-five (75%) had stage IV disease at initial diagnosis; two hundred eighty-four patients received first-line treatment, and dMMR/MSI-H testing was performed in two hundred fifty-one (84%) patients. The results of the dMMR/MSI-H tests were available in 61 (24%) of 251 patients before the diagnosis of metastatic disease and in 191 (81%) of 236 evaluable patients for this outcome before the initiation of first-line treatment. Among the 244 patients who were tested for dMMR/MSI-H with IHC or PCR, 14 (6%) were MMR deficient. The most frequent type of first-line treatment was the combination of chemotherapy and biological agent, that was received by 71% and 50% of patients with MMR proficient and deficient tumors, respectively, followed by chemotherapy alone, received in over 20% of patients in each subgroup. Only 29% of dMMR/MSI-H tumors received first-line immunotherapy.
Our study suggests that a high proportion of patients with mCRC are currently tested for dMMR/MSI-H in tertiary hospitals across Spain. However, there is still room for improvement until universal testing is achieved.
Not applicable.},
publisher = {Springer},
title = {Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain},
doi = {10.1007/s12094-023-03309-z},
journal = {Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
author = {Garcia-Carbonero, Rocio and González Astorga, Beatriz and Vidal Tocino, Rosario and Contreras Toledo, Débora and Pericay, Carles and Fernandez Montes, Ana and Falcó, Esther and González Cordero, Marta and Reina Zoilo, Juan José and Alonso, Vicente and Rodríguez Salas, Nuria and Gil-Raga, Mireia and Santos, Cristina and Páez, David and Anton-Pascual, Beatriz and Aguilar, Fernando and Morales, Pilar},
}